BCLI Brainstorm Cell Therapeutics Inc.

4.09
-0.10  -2%
Previous Close 4.19
Open 4.16
Price To book 10.49
Market Cap 77066749
Shares 18,842,726
Volume 32,143
Short Ratio 11.68
Av. Daily Volume 99,377

SEC filingsSee all SEC filings

  1. DEF 14A - Other definitive proxy statements 171085784
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171030307
  3. 8-K - Current report 17983741
  4. 8-K - Current report 17977080
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17841006

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released July 2016. Phase 3 trial to be initiated.
NurOwn
Amytrophic lateral sclerosis (ALS)

Latest News

  1. BCLI: Phase 3 Trial of NurOwn® to Initiate Soon
  2. Investor Network: Brainstorm Cell Therapeutics Inc. to Host Earnings Call
  3. BrainStorm Announces Second Quarter 2017 Financial Results
  4. Brainstorm to Host Second-Quarter 2017 Earnings Teleconference and Provide Important Corporate Updates, on Wednesday, August 16
  5. BrainStorm Supports Commitment to ALS Patient Community with Appointment of a Vice President of Patient Advocacy and Government Affairs
  6. BrainStorm Announces Agreement with University of California Irvine Medical Center to Participate in Phase 3 Trial of NurOwn® in ALS
  7. BCLI: Receives $16 Million Grant From CIRM to Fund Phase 3 Trial in ALS
  8. Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn® in ALS
  9. BrainStorm Announces Agreements with Mass. General Hospital and California Pacific Medical Center to Participate in Phase 3 Trial of NurOwn® in ALS
  10. Worldwide Clinical Trials Selected by BrainStorm as CRO for Phase 3 NurOwn Trial in ALS
  11. BrainStorm to Provide Corporate Update at the BIO International Convention
  12. BCLI: Phase 3 Trial of NurOwn® in Final Stages of Preparation
  13. BrainStorm Awarded $2.1 Million Non-Dilutive Grant for 2017 by the Israel Innovation Authority
  14. BrainStorm to Present at Cell & Gene Exchange Conference in Washington DC
  15. BrainStorm Initiated Technology Transfer to City of Hope for U.S. Production of NurOwn® for Phase 3 ALS Study
  16. BrainStorm Announces First Quarter 2017 Financial Results and Provides Corporate Update
  17. BCLI: Approval of Edaravone Shows FDA’s Eagerness to Approve New Treatments for ALS
  18. BrainStorm to Present at Two Scientific Conferences in May
  19. BrainStorm Announces Publication of NurOwn® Autism Research Study

SEC Filings

  1. DEF 14A - Other definitive proxy statements 171085784
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171030307
  3. 8-K - Current report 17983741
  4. 8-K - Current report 17977080
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17841006
  6. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17722237
  7. 8-K - Current report 17668045
  8. 8-K - Current report 17657080
  9. 8-K - Current report 162057741
  10. 8-K - Current report 162042869